Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 trial of recombinant HSV-1 expressing IL-12 (T-hIL12) in malignant melanoma
jRCT2033190086Phase 2Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jan 2020
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of T-hIL12 in melanoma (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Safety (Phase 1) and Response rate (RECIST 1.1) (Phase 2 primary). Started Jan 2020; status: recruiting.
02
Drugs
T-hIL12
03
Conditions
melanoma
Beyond the preview
Go deeper on jRCT2033190086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033190086.